iRadimed Corp. (IRMD) Trading Up 5.7%
Shares of iRadimed Corp. (NASDAQ:IRMD) were up 5.7% on Friday . The company traded as high as $22.53 and last traded at $22.13, with a volume of 65,765 shares. The stock had previously closed at $20.93.
A number of analysts have weighed in on IRMD shares. Roth Capital reissued a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd. Zacks Investment Research cut shares of iRadimed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, March 16th.
The stock has a market cap of $241.57 million and a price-to-earnings ratio of 33.18. The firm has a 50 day moving average price of $20.25 and a 200-day moving average price of $19.12.
iRadimed Corp. (NASDAQ:IRMD) last released its quarterly earnings results on Friday, April 29th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.18 by $0.03. During the same period in the prior year, the business earned $0.17 EPS. The firm earned $8.96 million during the quarter, compared to the consensus estimate of $9.05 million. The company’s revenue for the quarter was up 28.6% compared to the same quarter last year. Equities analysts expect that iRadimed Corp. will post $0.89 earnings per share for the current year.
In other news, Director Monty K. Allen sold 2,100 shares of iRadimed Corp. stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $20.44, for a total value of $42,924.00. Following the transaction, the director now owns 4,375 shares of the company’s stock, valued at $89,425. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Monty K. Allen sold 2,275 shares of iRadimed Corp. stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $20.00, for a total transaction of $45,500.00. The disclosure for this sale can be found here.
Several large investors recently made changes to their positions in the company. GSA Capital Partners LLP increased its stake in shares of iRadimed Corp. by 174.3% in the fourth quarter. GSA Capital Partners LLP now owns 50,203 shares of the company’s stock valued at $1,407,000 after buying an additional 31,901 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of iRadimed Corp. by 79.2% in the fourth quarter. AWM Investment Company Inc. now owns 278,330 shares of the company’s stock valued at $7,802,000 after buying an additional 123,000 shares during the last quarter. EAM Investors LLC increased its stake in shares of iRadimed Corp. by 0.4% in the fourth quarter. EAM Investors LLC now owns 78,945 shares of the company’s stock valued at $2,213,000 after buying an additional 311 shares during the last quarter. Finally, Russell Frank Co bought a new stake in shares of iRadimed Corp. during the fourth quarter valued at about $2,675,000.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.